L. Azoulay

First name
L.
Last name
Azoulay
Abrahami, D., Yin, H., H. Y. Yu, O., Pollak, M. N., & Azoulay, L. (2018). Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes. Epidemiology. http://doi.org/10.1097/ede.0000000000000793
View
Douros, A., Filion, K. B., Yin, H., Yu, O. H., Etminan, M., Udell, J. A., & Azoulay, L. (2018). Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy. Diabetes Care. http://doi.org/10.2337/dc17-2280
View
Abrahami, D., Douros, A., Yin, H., H. Y. Yu, O., Renoux, C., Bitton, A., & Azoulay, L. (2018). Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. Bmj. http://doi.org/10.1136/bmj.k872
View
Santella, C., Renoux, C., Yin, H., H. Y. Yu, O., & Azoulay, L. (2019). Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men with Late-Onset Hypogonadism. Am J Epidemiol. http://doi.org/10.1093/aje/kwz138
View
Pradhan, R., Yin, H., H. Y. Yu, O., & Azoulay, L. (2019). The Use of Long-Acting Insulin Analogs and the Risk of Colorectal Cancer Among Patients with Type 2 Diabetes: A Population-Based Cohort Study. Drug Saf. http://doi.org/10.1007/s40264-019-00892-5
View
Hicks, B. M., Filion, K. B., Yin, H., Sakr, L., Udell, J. A., & Azoulay, L. (2018). Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. Bmj. http://doi.org/10.1136/bmj.k4209
View
Khosrow-Khavar, F., Yin, H., Barkun, A., Bouganim, N., & Azoulay, L. (2018). Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer. Ann Oncol. http://doi.org/10.1093/annonc/mdx822
View
Abrahami, D., Douros, A., Yin, H., H. Y. Yu, O., & Azoulay, L. (2019). Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes. Diabetes Care. http://doi.org/10.2337/dc19-0849
View
Filion, K. B., Douros, A., Azoulay, L., Yin, H., Yu, O. H., & Suissa, S. (2019). Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.14056
View
Douros, A., Rouette, J., Yin, H., H. Y. Yu, O., Filion, K. B., & Azoulay, L. (2019). Dipeptidyl Peptidase-4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes. Diabetes Care. http://doi.org/10.2337/dc19-0409
View